ARMATA PHARMACEUTICALS, INC. Tax Withholding Paid on Stock Awards
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Tax Withholding Paid on Stock Awards of $63.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $63.00K, a 350.00% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $32.00K.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $46.00K, a 24.59% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $61.00K, a 41.86% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $43.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $63.00K 10-Q · filed 2026-08-12 | $63.00K derived: sum of 3 quarters · filed 2026-08-12 | $95.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-13 | $63.00K derived: sum of 2 quarters · filed 2026-05-13 | $95.00K derived: sum of 3 quarters · filed 2026-05-13 | $95.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $32.00K derived: sum of 2 quarters · filed 2026-03-25 | $32.00K derived: sum of 3 quarters · filed 2026-08-12 | $46.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $32.00K derived: sum of 2 quarters · filed 2026-08-12 | $46.00K 10-Q · filed 2025-11-12 | $46.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.00K 10-Q · filed 2026-08-12 | $14.00K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-13 | $14.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $61.00K 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $61.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $43.00K 10-K · filed 2025-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |